Time- and pH- dependent proteolysis of Engineered Proteins by Collagenase by Berry, Hunter
University of Mississippi
eGrove
Honors Theses Honors College (Sally McDonnell BarksdaleHonors College)
2019
Time- and pH- dependent proteolysis of
Engineered Proteins by Collagenase
Hunter Berry
University of Mississippi, haberry1@go.olemiss.edu
Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Biochemistry Commons
This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell Barksdale Honors College) at eGrove. It
has been accepted for inclusion in Honors Theses by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.
Recommended Citation
Berry, Hunter, "Time- and pH- dependent proteolysis of Engineered Proteins by Collagenase" (2019). Honors Theses. 1183.
https://egrove.olemiss.edu/hon_thesis/1183
Time- and pH- dependent proteolysis of Engineered Proteins by Collagenase 
 
 
 
 
 
By 
Hunter Allen Berry 
 
 
 
 
 
A Thesis submitted to the faculty of The University of Mississippi in partial fulfillment of 
the requirements of the Sally McDonnell Barksdale Honors College. 
 
 
 
 
Oxford 
April 2019 
 
 
 
 
 
 
 
Approved By: 
 
_______________________________ 
Advisor: Professor Susan Pedigo 
 
 
_______________________________ 
Reader: Professor Gregory Tschumper 
 
 
_______________________________ 
Reader: Professor Davita Watkins 
 
	 ii	
 
 																																		
©	2019	Hunter	Allen	Berry	ALL	RIGHTS	RESERVED	
ABSTRACT 
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Hunter Allen Berry: Time- and pH- dependent proteolysis of Engineered Proteins by 
Collagenase. 
(Under the direction of Dr. Susan Pedigo) 
 
 Pleiotropic effects from oral administration of anti-inflammatory drugs limit their 
effectiveness. The ultimate goal of this project is to develop a novel self-assembling 
protein-based hydrogel for in situ delivery of NSAIDs at the site of chronic inflammation.  
Since inflammation causes acidification and activation of collagenases in the inflamed 
tissue, we have designed the hydrogel to respond to both of these queues to effectively 
deliver drug at the site. Self-assembly of the protein hydrogel exploits the high affinity 
and specific interaction between the protein calmodulin (CaM) and its specific binding 
peptide, M13. The two components of the hydrogel, CCLP and PCLP contain repeats of 
CaM and M13 domains, respectively, which are separated by engineered collagen-like-
sequences (CLS).  Proteolysis of the protein hydrogel formed by PCLP and CCLP by 
collagenases will cause exposure of the protomers and release of drug at the site. This 
important aspect of this responsive material requires susceptibility to relevant proteases, 
and is the specific subject of the present study. Exposure of CCLP to collagenase, and 
MMP-1, indicates that each protomer is susceptible to cleavage in the CLS sequences. 
This conclusion was confirmed by SDS-PAGE of cleaved CCLP. Further proof, through 
use of MALDI-TOF, was required in order to more precisely characterize fragment 
identity; however, lack of access to current working negative mode MALDI-TOF 
prohibited precise molecular weight quantification of fragment bands. Initial studies have 
	 iv	
prompted iterations of the component protomers. Further, we have demonstrated that the 
hydrogel is also susceptible to cleavage by collagenases. Results indicate the pH and 
Temperature dependent degradation of Engineered Proteins by collagenase require 
investigation into other degradable sequences as substitutes for current CLS to better 
improve lifetime in inflammatory conditions. Also, future research into kinetic profiles of 
the degradation of PCLP and CCLP by MMPs are necessary for optimizing the lifetime 
of the hydrogel for in-situ drug delivery. 																											
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CHAPTER 1 
INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common 
nonprescription drugs in the US and internationally. Traditional oral administration of 
NSAIDs as anti-inflammatory therapeutics induces systemic harm in the gastrointestinal, 
renal, and cardiovascular systems.1 The adverse side effects of systemic administration of 
NSAIDs necessitate research into alternative methods for administering drug. In-situ drug 
delivery using a hydrogel scaffold system for spatial and time-sensitive drug release 
bypasses many systemic complications. Our lab is developing a novel protein-based 
hydrogel by taking advantage of the calcium-sensitive, high affinity interaction between 
calmodulin (CaM) and the peptide M13. A critical feature of our hydrogel is its ability to 
respond to the conditions in inflamed tissues, namely the lower pH and presence of 
particular proteases that are specific for remodeling the collagen network. Here, we will 
describe novel CaM- and M13-based protomers previously demonstrated to form a 
protein hydrogel, which include CCLP3, CCLP2, CCLP3 bis-Cys, and PCLP3. Each of 
these protomers is designed to be a substrate for Matrix Metalloproteinases (MMPs). 
MMPs are naturally present in the ECM to remodel the collagen network for tissue 
growth and repair of injuries 4. We have engineered collagen-like sequences into our 
hydrogel protomers to allow for steady degradation and drug release in inflamed tissues. 
Due to decreased pH in inflamed tissue, an understanding of pH- and time-dependent 
proteolysis of CCLP3, CCLP2 and CCLP3 bis-Cys is needed to assess the in vivo 
lifetime and responsiveness of the resultant hydrogels.  PCLP3 was not included in initial 
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protomer proteolysis studies due to solubility issues. PCLP3 is only soluble in 6M urea, 
which denatures collagenase, rendering it inactive.  
 
Inflammation 
 Inflammation is a physiological response meant to address harmful stimuli such 
as infection, damaged tissue, or abnormal increases in stress 2. Due to the highly complex 
dynamic wound healing process that includes intricate interactions between ECM 
molecules, inflammatory mediators, resident cells and infiltrating leukocytes, the healing 
process is generally divided into three separate phases, which are time and spatially 
dependent on each other. Inflammation, Tissue formation, and Tissue remodeling are the 
three phases. Following tissue injury, acute inflammation begins with pro-inflammatory 
mediator and cytokine release from resident Mast Cells, Macrophages, monocytes, and 
non-immune cells such as fibroblasts and endothelial cells3. Pro-inflammatory cytokines 
have been determined to be strong inducers of various Matrix-metalloproteinases. MMPs 
contribute to many of the inflammatory processes following induction. By modulating 
inflammatory mediators, such as chemokines and cytokines, regulating physical barriers, 
and establishing chemokine gradients for movement of leukocytes to site of injury and 
infection, MMPs assist in each step of the healing process4. In order to aid the delivery of 
inflammatory mediators and inflammatory cells, Nitric oxide, and prostaglandin 
vasodilation are released. Histamine, Bradykinin, and leukotrienes act in conjunction 
with the vasodilators to force protein rich fluid into the inflamed tissue. These processes 
are accompanied by neutrophil delivery to the site of inflammation4. Neutrophils and 
Macrophages then begin the process of phagocytizing infectious agents and debridement 
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of dead tissue3. MMPs also assist in the anti-inflammatory response, if the stimulation of 
the inflammatory response has subsided, by acting to clear the inflammatory cells from 
the healed wound5. If the stimulation of the inflammatory response is terminated, the 
acute inflammatory response is resolved, however, if the stimulation of the inflammatory 
response continues, chronic inflammatory disease can arise, such as diabetes, cancer, 
cardiovascular diseases and autoimmune diseases6. 
 
Chemical and pH component of pain in inflammation 
There are many inflammatory mediators throughout the inflammatory response that are 
related to the pathological aspect of inflammation, such as the pro-inflammatory 
cytokines IL-1B, IL-6, and TNF-α7.  Studies have also shown that other inflammatory 
mediators, such as Prostaglandin E2, Bradykinin, Histamine and serotonin also induce 
nociception in inflamed tissue. Additionally, the inflammatory response increases the 
acidity of the surrounding ECM, which also plays a role in the pathological response8.   
 Studies have shown that lowered pH, which is a product of the inflammatory 
response, also has an effect on pathological aspect of inflammation. The presence of high 
proton concentration is apparent in inflammation, as well as in malignant tumors and 
other acute injuries such as fracture-related hematomas, resulting in pH as low as 5.89. 
This phenomenon is due to leukocytes present in the inflamed tissue that actively excrete 
lactate into the ECM as they act to combat the harmful inflammatory stimuli, 
Extracellular lactate decreases the pH of the inflamed tissue, which causes a painful 
stimulation. A study of the combination of inflammatory mediators, Histamine, Bradykin, 
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5-HT, and Prostaglandin E2 with low pH showed synergistic combination with regards to 
nociceptor stimulation9. 
 This form of pain, that which is induced by the inflammatory response, is meant 
to be an adaptation that results in a protective mechanism. The increase in sensory 
sensitivity, during unavoidable tissue damage, such as with chronic inflammation of 
tissue, discourages physical contact to and movement of, the place of inflammation. The 
nociceptors, which are receptors for pain, have become sensitized during the 
inflammatory response in order to increase awareness and protection of the inflamed 
tissue10. 
 Additionally, the onset of fever is also an adaptive mechanism, which works to 
aid in combatting invasive species and healing. Following the induction of the 
inflammatory response, other cytokines are produced that are called endogenous 
pyrogens. Through further signaling cascade, and production of prostaglandins, the 
endogenous pyrogens induce an increase in temperature. This increase in temperature is 
an adaptive mechanism that is meant to inhibit bacterial growth, increase bactericidal 
activities of neutrophils and macrophages. This adaptive mechanism is why inflamed and 
healing tissue feels hot to the touch10.  
 
Acute and Chronic inflammation 
 There are two stages of the inflammation response depending on the length of 
time that pathological effects persist. Acute inflammation, as previously mentioned, is an 
adaptive response meant to resolve any disease, harmful stimulus or foreign stimulus and 
persists for approximately 24 hours. Chronic inflammation, which persists for a 
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prolonged period of time, is harmful due to the inability to terminate the initiating 
inflammatory stimulus. An overly activated immune or repair system is an expensive 
energy consuming mechanism that is marked by sickly prognoses, as well as loss of 
appetite. On a cellular level, the continual inflammatory response leads to chronic 
inflammatory diseases, such as cancer, diabetes, cardiovascular disease, and autoimmune 
diseases11.  
 
Adverse side effects of systemic administration of NSAIDs 
 NSAIDs are prescribed for their painkilling, anti-inflammatory, therapeutic 
effects, but have adverse side effects such as gastrointestinal, cardiovascular, and renal 
complications (Figure 1.1). The therapeutic benefit comes primarily from the ability of 
NSAIDs to block specific prostaglandin synthesis, through inhibition of the 
cyclooxygenase enzymes COX-1 and COX-2. COX-1 is expressed in normal cells, and 
primarily deals with physiological housekeeping mechanisms, whereas COX-2 is not 
normally expressed, unless inflammation occurs, when it is then induced and is 
significantly unregulated. COX-1 inhibition is an undesired effect of the use of NSAIDs; 
this is because COX-1 produces prostaglandins and thromboxane A2, which control 
physiological functions as well as the mucosal barrier in the GI tract, renal homeostasis 
and platelet aggregation. Inhibition of COX-1 is what leads to gastrointestinal and renal 
toxicities, as well as cardiovascular complications. COX-2 inhibition is the intended 
effect of NSAIDs, due to its production of prostaglandins that are related to the 
pathological aspect of inflammatory responses such as pain and fever12.  
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Figure 1.1. The adverse side effects of inhibition of COX-1 and COX-2 inhibition by 
NSAIDS. Inhibition of COX-1 and COX-2 has inflammatory pathologically non-specific 
effects, such as prostaglandin synthesis inhibition, which has adverse side effects on the 
kidney, GI and cardiovascular systems. 
(Figure taken from http://tmedweb.tulane.edu/pharmwiki/doku.php/nsaid_side_effects ) 
 
 
Utilizing ECM conditions for drug release 
 In order to effectively bypass the systemic side effects that occur when NSAIDs 
are administered orally, specific conditions of the site of inflammation can be exploited to 
delivery drugs locally. In inflamed tissue, Matrix Metalloproteinases expression is 
significantly upregulated by many inflammatory cytokines, such as tumor necrosis factor 
and by growth factors such as, epithelial growth factor. Normally secreted as an inactive 
form, proteinases, reactive oxygen and hypochlorous acid generated by leukocytes, all 
due to the inflammatory response, activate Matrix-Metalloproteinases to aid in healing. 
By utilizing the conditions and enzymatic composition of the ECM in inflamed tissue, 
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novel protein hydrogels formed from CCLP and PCLP, which contain MMP substrate 
cleavage sites, can be used for inflammation responsive drug release4. 
 
Matrix Metalloproteinases (MMPs) 
 MMPs family contains 23 related human proteinases that are not only involved in 
tissue remodeling, but also in cleavage of specific substrates capable of secondary 
biological activity, and in indirect and direct modification of signaling molecules and in 
creating the means for cellular migration the 3D-space of tissues. There are three domains 
in the structure of all MMP’s, the pro-peptide, hemopexin and catalytic domains. The 
pro-domain contains a cysteine residue that inhibits catalysis by coordinating with the 
active site zone. The pro-domain is removed, exposing the active site, which controls 
MMP’s ability to cleave substrates. The hemopexin domain mediates protein-protein 
interactions, and plays a large role in proper substrate recognition, activation of the 
enzyme, protease localization, internalization and degradation. By regulating the proteins 
composing the extracellular matrix, MMPs can affect a wide range of extracellular and 
intracellular functions of cells. There are countless substrates of MMPs, such as peptide 
growth factors, cell-adhesion molecules, cytokines and chemokines, producing varying 
secondary mechanisms, leading to a complex, yet diverse characterization of MMPs. 
Further research into the MMP family began upon finding that MMPs are unregulated in 
many forms of human diseases, such as arthritis and cancer5. 
 Inflammation is crucial for the protection of the human body, however, if 
unregulated or excessive in nature, inflammation can lead to further tissue injury, chronic 
disease or organ dysfunction, as previously mentioned. Matrix Metalloproteinases are 
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crucial to the inflammatory process, by either stopping or furthering the pathological 
effects of the inflammation. MMPs regulation of inflammation is dependent on the 
location, specific MMP, and availability of substrate4. In nearly all forms of human 
disease that utilize inflammation, increased expression of MMPs has been observed. 
Although specific substrates of MMPs have been, for the most part, undefined, catalytic 
effectiveness of specific cleavable sequences has been determined for target substrates. In 
particular, the collagen type-1 derived sequence, GPQG / IWGQ, which is present in 
CCLP3, CCLP2 and CCLP bis-Cys, has been shown to be catalytically degraded by both 
MMP-1 and MMP-813.  
 
 
MMP-1 and MMP-8 
 Matrix Metalloproteinase 1 was first discovered to degrade fibrillar collagen in 
tadpole tales in 1962, and was then characterized as interstitial collagenase. Following the 
discovery, a large field of study began to determine the role of MMP-1 in a pathological 
and physiological setting. MMP-1 is a part of a subgroup of soluble proteases known as 
collagenases. With regards to substrate specificity, MMP-1 is able to degrade a wide 
variety of substrates, allowing it to be the most versatile of all the MMPs. MMP-1 is 
catalytically active in the process of overturning the extracellular matrix; therefore, it has 
been hypothesized that many diseases that result from excessive or insufficient 
extracellular matrix turnover, such as arthritis are linked to deregulation of MMP-1. 
MMP-1 expression is correlated to oxidative stress, which is significantly higher in 
inflamed tissue. 
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 Matrix Metalloproteinase 8 Matrix Metalloproteinase 8 is a soluble proteinase, 
known as a collagenase, similar to MMP-1 in both structure and function. The differences 
lie in either MMP having subtlety greater affinities for specific substrates. MMP-8 is 
unregulated during oxidative stress, just as MMP-1, which corresponds to the increased 
turnover of ECM during inflamed tissue14. 
 
Alternative method of drug delivery 
 In order to combat the adverse effects associated with systemic administration, 
targeted drug delivery systems (DDSs) have been under extensive research. Targeted 
DDSs have many benefits, such as improvement in absorption, distribution, metabolism, 
and excretion of drugs. By increasing the solubility of drugs that have hydrophobic 
molecular structures or altering the pathway of drug administration, targeted DDSs help 
to increase the overall absorption of specific drugs. Traditionally, the systemic 
distribution of drugs allows no control for the spatial aim or utilization of a time-based 
release to optimize the analgesic and anti-inflammatory effects of NSAIDs. Targeted 
DDSs allow for specific targeting of inflamed tissue, as well as a response mediated by 
inflammation, providing an efficient drug effect. Alteration of drugs so that excretion is 
possible is primarily the job of the liver and kidneys. Drugs that are administered orally 
are absorbed through the gastrointestinal tract and must first pass through the liver before 
being released into systemic circulation. In the liver, many drugs undergo chemical 
reactions that alter or increase the activity of enzymes before release into the bloodstream 
for intended effects on target tissues. Following the intended effects of the NSAIDs, the 
kidneys must also work to clear them from the blood. The metabolic pathways through 
	 10	
which drugs enter and exit the systemic network of the body leads to potential for liver 
and kidney toxicity. Administration through targeted DDSs could allow for alternate 
administration and clearance mechanisms that could negate the systemic issues associated 
with NSAIDs15.  
 
Calmodulin and M13 
Calmodulin is a 148 residue long, dumbbell shaped molecule, with two EF-hand 
Ca2+-binding sites in both the N- and C-terminal domains and a central helix connecting 
the two. In solution, the central helix adopts an unstructured conformation16, which 
allows the Calmodulin-Ca2+ complexes freedom to conform completely to the structure 
of the target peptide (Figure 1.2). M13 is a 26 residue long peptide that binds the 
Calmodulin-binding domain of skeletal muscle myosin light chain kinase. Upon binding 
of M13 to the Calmodulin-Ca2+ domain, the conformational change in the central helix of 
Calmodulin-Ca2+ causes the Calmodulin- Ca2+ binding domain to fold around the M13, 
forming a tight hold17. M13 also undergoes a conformational change upon complex with 
Calmodulin-Ca2+, from an undefined random coil in its apo state to a helical 
conformation upon binding to Calmodulin-Ca2+, further assisting in the strength of 
binding18. The Calmodulin-M13 complex is primarily stabilized by hydrophobic 
interactions19. Utilization of the Calcium dependent Calmodulin-peptide interaction 
causes self-assembly of Engineered protein components, CCLP and PCLP, resulting in 
non-covalent cross-linking formation of a hydrogel. 
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Figure 1.2. Complex of Calmodulin and M13. A. The ribbon drawing of calcium bound 
Calmodulin20. B. The schematic depiction of apo Calcium-Ca2+ binding domains. C. The 
ribbon drawing of Calmodulin-Ca2+ complex with the M13 peptide21. D. The schematic 
depiction of the Calmodulin-Ca2+ complex with the M13 peptide depicts the conforming 
of the Calmodulin-Ca2+ domain tightly to the M13 domain.  
 
 
 
 
 
PCLP and CCLP and hydrogel formation 
 Hydrogels are hydrophilic, polymer-based substances with physiologically 
compatible characteristics, capable of countless therapeutic benefits. Constituents of 
hydrogels can be synthetic in origin, such as poly(ethylene glycol) (PEG), 
polyacrylamide (PAM), poly(vinyl alcohol) (PVA), and poly(methyl methacrylate) 
(PMMA), or naturally occurring polymers, such as collagen, gelatin, chitosan, and 
alginate. There are limitations to these single polymer, synthetic, and naturally occurring 
hydrogels, which prompts the engineering of more complicated, but promising, hydrogels 
composed of co-polymers. Co-polymer hydrogels are composed of crosslinking polymers 
that are a mesh-like network formed by binding oligomer chains within a polymeric 
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scaffold that was previously assembled. Hydrogel materials of this nature are susceptible 
to specific modification to mimic conditions in the extracellular matrix to better control 
the therapeutic outcome22. CCLP and PCLP are engineered proteins capable of forming a 
co-polymer cross-linking that exhibit physical hydrogel properties capable of degradation 
by ECM enzymes.	A	schematic	of	the	formation	of	our	protein-based	hydrogels	is	shown	in	Figure	1.3.	Actual	photographs	of	our	hydrogels	are	shown	in	Figure	1.4. 
 
 
Figure 1.3. Schematic of hydrogel formation. The multiple peptide complex of CCLP 
and PCLP (n=2 or n=3) form a mesh-like hydrogel with multiple sites of interaction. The 
CCLP and CCLP proteins and the resultant hydrogel are susceptible to enzyme specific 
degradation (Figure taken from Pedigo lab). 
 
 
Figure 1.4. The formation of a 10% hydrogel from PCLP and CCLP (Courtesy of 
Christopher Fox). Three images of the same hydrogel, with and without overlaying 
aqueous buffer. 
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Goal of Experiments 
 The specific goal of the experiments reported here is to test the susceptibility of 
the engineered protomers to degradation by collagenase, and various MMPs. The studies 
address susceptibility to cleavage of specific target sequences by collagenase, MMP-1 
and MMP-8, and the effects of degradation rate as a function of pH and time. All assays 
of enzyme activity are performed by gel assays of degradation products. Finally, initial 
studies of the proteolytic degradation of the gels themselves as a function of pH and time. 
Results from these studies create a foundation for re-engineering the component 
protomers to change the in vivo lifetime of the gel matrix.    
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CHAPTER 2 
 
MATERIALS AND EXPERIMENTAL PROCEDURES 
 
Materials 
All materials were standard chemicals available from suppliers unless otherwise 
noted. 
Materials for Overexpression 
Bacto Agar 
Tryptone 
Yeast Extract 
NaCl 
250 mL Erlenmeyer Flasks 
100 x 20 mm polystyrene culture dishes 
Kanamycin (1000x stock- 30 mg/ml in water) 
Inoculation loops 
1M potassium Phosphate, pH 7.4, sterile 
Isopropylthiogalactoside (IPTG) 0.4M, sterile 
Spectrophotometer 
Disposable Cuvettes, narrow width, 1cm path length 
0.8 L centrifuge bottles 
Centrifuge 
 
Materials for Purification 
Stationary Phases 
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His-Tag: Immobilized Nitrilotriacetic Acid with Ni(II) (Thermofisher)  
Hydrophobic Interaction: Phenyl Sepharose (Amershan Biosciences) 
HisTag Buffers: 
Binding Buffer: 20mM Tris, 0.5 M NaCl, 5 mM Imidazole, 6 M Urea, pH 7.9 
Wash Buffer: 20mM Tris, 0.5 M NaCl, 40 mM Imidazole, 6 M Urea, pH 7.9 
Elution Buffer: 10mM Tris, 250 mM NaCl, 0.5 M Imidazole, 6 M Urea, pH 7.9 
*Buffers were filtered through 0.45 µm filter prior to use. 
Hydrophobic Interaction Buffers: 
A: 20 mM Tris, 50 mM CaCl2, 50 mM NaCl, pH 7.4. 
B: 20 mM Tris, 50 mM CaCl2, 500 mM NaCl, pH 7.4. 
C: 20 mM Tris, 10 mM EDTA, 50 mM NaCl, pH 7.4. 
 
Materials for Proteolysis 
MMP and Collagenase Digest Buffers: 
Tris digest Buffer: 100 mM Tris, 100 mM NaCl, 10 mM CaCl2, pH 7.4 
MES digest Buffer: 100 mM MES, 100 mM NaCl, 10 mM CaCl2, pH 5.7 & pH 6.5 
200 nM Collagenase Stock (Sigma Aldrich) 
20 nM MMP-1 & MMP-8 Stocks (Anaspec) 
2X SDS Reducing Loading Buffer 
SEC Buffer: 10 mM HEPES, 140 mM NaCl, 6 M urea, pH 7.4 
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Experimental Procedures 
The purpose behind this experiment is to produce the PCLP and CCLP proteins, 
which are the two required components for the formation of the hydrogel, and 
characterize their degradation under certain physiological conditions. We synthesized the 
proteins using a bacterial expression system of genes in engineered plasmids. We 
prepared overnight cultures, which were inoculated with freshly plated, pre-transformed 
cells, which were then used to inoculate large LB-Kanamycin cultures. Large cultures 
were grown to mid log phase, and then induced with IPTG allowing bacteria to express 
protein. Following expression period, cells were separated from supernatant, sonicated 
and centrifuged in order to isolate protein. Protein was purified using either His-Tag 
chromatography or hydrophobic interaction chromatography. Following purification, 
protein was lyophilized and stored in freezer at -20o C. 
 Lyophilized protein was weighed and re-suspended in three different digest 
buffers: MES Buffer pH 5.7, MES Buffer pH 6.5 and Tris Buffer pH 7.4, resulting in a 
final concentrations of 200 µM. We made a collagenase stock in each of the respective 
buffers, resulting in a 2 µM solution. We performed digests of CCLP3, CCLP2 and 
CCLP3 bis-Cys by collagenase in 100 µL to test whether the proteins were susceptible to 
proteolysis. Sample points for general collagenase proteolysis were 0 hr and 48 hr. We 
performed SDS-PAGE on pre- and post-digest protein samples in order to visually 
observe digest occurring. In order to accurate visualize band density diminishing, digest 
samples were diluted to a final concentration of 10 µM, corresponding to a 20:1 dilution 
of all other components of the digest before running on SDS-PAGE. Subsequently, we 
tested pH dependent proteolysis by collagenase of engineered proteins. We made 230 µM 
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CCLP3, and CCLP2 stocks and 200 µM collagenase stocks at pH 5.7, 6.5, and 7.4. 
Engineered proteins and collagenase were combined to form 200 µL of digests of 200 
µM CCLP3 and CCLP2 and 200 nM collagenase at pH 5.7, 6.5 and 7.4. Time points 
were taken on an exponential scale as follows- 0 min, 10 min, 20 min, 40 min, 80 min, 
160 min, 320 min, 640 min, 1280 min. Due to concern of Ca2+ having an impact on band 
migration distances in SDS-PAGE, additional 1280 min samples were treated with 600 
µM EDTA in order to chelate the Ca2+ ions. (Calcium concentration following dilutions 
was 500 µM.) Samples were then run on SDS-PAGE, and trend lines for all digests were 
created. Following general collagenase digests, we made 230 µM stocks of CCLP3, and 
CCLP2 and 100nm stocks of MMP-1 and MMP-8. Following apparent activation of 
MMP-1, and MMP-8, Engineered proteins were combined with MMP-1 and MMP-8 in 
separate 25µL digests of 20nm MMP-1, and MMP-8, and 50 µM engineered protein. We 
took sample time points, 0 min, 30 min, and 1, 2, 4, 8, 16, 32, and 64 hrs in order to test 
the susceptibility of engineered proteins to proteolysis of specific MMPs. SDS-PAGE 
was performed on each protein digest in order to visualize proteolytic fragments.  
 
Methods 
The following section provides details of the procedures that were followed.  
Preparation of Overnight 
 We inoculated LB Agar plates with the pre-transformed cells, preparing isolated 
colonies by using a streaking method throughout the plate. Cultures were grown 
overnight at approximately 37o C. The following day, we acquired a well-defined colony 
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from the agar plates, and then inoculated into the 50 mL LB containing Kanamycin. The 
50mL culture grew overnight at 37o C in the incubator, rotating at 250 rpm.  
 
Protein Overexpression 
 Experimenters inoculated 1L LB Kanamycin with 5 mL from the 50 mL 
overnight culture, then placed them in 37o C incubator at 250 rpm. Absorbance of the 
expression cultures was monitored at 600 nm. When the AU reached 0.6-1.0, expression 
was induced by addition of 1 mL of 0.4 M IPTG into each large culture, resulting in a 
final concentration of 0.4 mM IPTG. Large cultures then incubated at 37o C for 2 
additional hours at 250 rpm.  
 
Centrifugation 
 We harvested the cells by transferring the cultures into 1L centrifuge bottles, 
which can hold approximately 800 mL. A 1mL post induction sample was taken, and 
cultures were centrifuged for 15 minutes at 3000 rpm. We decanted and discarded the 
supernatant. The cells were re-suspended in approximately 10 mL of 20 mM HEPES, 100 
mM KCl, pH 7.4 buffer. We then transferred the cells to a metal beaker, covered them 
with parafilm and froze them at -20o C. 
 
Fractionation and Purification  
 We thawed the cells, and then sonicated them for 5 minutes at 50% amplitude, 5 
seconds on and 5 seconds off. We took a post sonication sample for SDS-PAGE analysis, 
and then centrifuged the sonicated cells at 13,000 rpm for 45 minutes. Soluble protein 
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was decanted from the pellet and ready for chromatography. Insoluble protein was in the 
pellet, and required Triton-X washes. Following decanting of the supernatant, we added 
15 mL of 10% Triton-X to the pellet, stirred the pellet up, and incubated it at room temp 
for 10 minutes. We centrifuged the 10% Triton-X suspension at 13,000 rpm for 20 
minutes. Following centrifugation, we took a supernatant sample, and then decanted the 
rest. We added 15 mL of 1% Triton-X to the pellet, resuspended the pellet, and then 
incubated at room temp for 10 minutes. We centrifuged the 1% Triton-X suspension at 
13,000 rpm for 20 minutes. The pellet was resuspended in 1% Triton-X, and then 
incubated it at room temp for 10 minutes. The 1% Triton-X suspension was then 
centrifuged at 13,000 rpm for 20 minutes. Following centrifugation, we took a sample 
and decanted off the supernatant, leaving a washed pellet with high protein content. The 
pellet was then dissolved in His Tag Binding Buffer containing 6M urea. 
 His Tag chromatography was utilized in order to purify the insoluble protein 
following centrifugation and fractionation. The histidine residues cause the protein to 
adhere to Nickel (II) in the column’s stationary phase. Column was equilibrated in 25 mL 
of Binding Buffer containing 6 M urea. Once columns are equilibrated, we loaded 5 mL 
of crude protein in 6 M urea onto the column and collected the eluent in a conical labeled 
Flow Through. We loaded a total of 25 mL Binding Buffer with 6 M Urea onto the 
column, collecting 5 mL fractions labeled BB-1 through BB-5. A total of 25 mL of Wash 
Buffer with 6 M urea was loaded onto the column and collected in 5 fractions labeled 
WB-1 through WB-5. We loaded 40 mL of Elution Buffer onto the column, collecting 5 
mL in EB-1, then 10 mL in EB-2 and EB-3, and 5 mL in EB-4, EB-5 and EB-6. We 
determined which elution fractions contained protein by checking absorbance against 
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corrected for a Binding Buffer sample. After determining which EB fractions contained 
protein, we dialyzed the protein into SEC Buffer (10 mM HEPES, 140 mM NaCl, 6 M 
urea, pH 7.4). Protein stock was stored in the freezer. 
Soluble protein is first heated in the presence of calcium to 80o C for 10 minutes 
to precipitate contaminating proteins. The supernatant contains soluble protein. The 
hydrophobic residues present in the protein allow the protein to adhere to the 
hydrophobic stationary phase of the column. This technique was used to purify the CCLP 
constructs. In the presence of calcium and low salt (Buffer A), calmodulin adsorbs to the 
column. Then the column is washed with buffer B (high calcium and low salt) to remove 
nonspecifically adsorbed contaminants. The column is then washed with Buffer A again. 
Finally protein is eluted with Buffer C (low calcium, low salt). Elution fractions contain 
purified protein, which is then dialyzed into water and lyophilized. 
 
Proteolysis Experiments 
 We used the lyophilized protein stocks to make 200 µM solutions of CCLP3, 
CCLP2 and CCLP bis-Cys (in SEC Buffer), and also made a 100 µM collagenase stock 
and a 13 mM sodium azide solution. Stock solutions were diluted and combined into a  
100 µL solution of 200µM protein, 2µM collagenase, and 0.05% sodium azide. We then 
took 10 µL samples at 0hr digest time point and a 48hr digest time point, using 10µL of 
2X SDS reducing buffer to quench the reaction. Once time points were gathered for each 
protein, we ran each sample on a gel in order to observe the degree of cleavage.  
 Following observation of cleavage of engineered proteins by collagenase, we then 
tested the pH dependence of collagenase. We made 230 µM stocks of CCLP3, and 
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CCLP2, and made a 1.48 µM stock of collagenase at three different pH 5.7, 6.5, and 7.4. 
We calculated the volume of each required component stock, 230 µM CCLP3, and 
CCLP2, and 1.48 µM collagenase stock, in order to result in a 200 µL digest consisting of 
200 µM CCLP3, and CCLP2, and 200 nM collagenase. We then combined the CCLP3, 
CCLP2, and Collagenase to result in three different 200 µL of a 200 µM CCLP3/CCLP2, 
200 nm collagenase digests, at pH 5.7, 6.5 and 7.4. 
 After observing pH dependent cleavage by collagenase, we began proteolysis 
experiments with MMP-1 and MMP-8. We activated MMP-1, and MMP-8 by incubating 
them at 37o C with 1mM APMA for 3 hours and 1 hour respectively. Following 
activation, we began the digest of CCLP3, and CCLP2 by MMP-1, and MMP-8. CCLP3 
and CCLP2 concentrations were 50 µM, and MMP-1 and MMP-8 concentrations were 20 
nM. Leftover activated MMP time points were taken for 0hr, 1 hr, 2 hr and 4 hr post 
activation, and digest time points were taken at 0 hr, 16 hr, 24 hr, 48 hr, and 72 hr. 
Samples were run on SDS-PAGE in order to visualize cleavage. 
 
 
 
 
 
 
 
 
 
	 22	
CHAPTER 3  
RESULTS AND DISCUSSION 
The objective was to prove that the theoretical cleavage of novel proteins was 
possible by collagenase. In order to analyze the proteolytic susceptibility of our 
engineered proteins by collagenase, we used SDS-PAGE to visualize the effects of a 
digest. We ran a standard molecular weight protein ladder, with known molecular weight 
bands, to use as a comparative tool for determining if cleavage of the main protein bands 
was occurring, and if so, what fragment pieces were being produced from the cleavage. 
As shown in Figure 2.1, each engineered protein and its subsequent digests are grouped 
on the gel. For each digest, a protein stock and a collagenase stock were run in order to 
eliminate the possibility of incorrectly identifying protein or collagenase bands as 
digested protein fragments on the gel. The engineered protein stocks before and after 
digestion with collagenase were the same concentration to accurately assess whether a 
band’s density was diminished. As depicted in Figure 2.1, the CCLP3, and CCLP3 bis-
Cys protein stocks, which correspond to lanes 2 and 8 respectively, migrated according to 
their molecular weight, right above the 45,000 D band in the molecular weight standard. 
CCLP2 stock, which corresponds to lane 5, migrated just below the 45,000 D, indicating 
it is also migrating according to its molecular weight. As shown by the 48-hour digest 
point in lanes 4, 7, and 10, the main band formed migrated to approximately 16,000 D, 
indicating that collagenase cleaved at the correct points, producing Calmodulin. We 
initially planned to use MALDI-TOF in order to identify the precise molecular weights of 
each respective band, but the negative mode of the MALDI-TOF machine was not 
working, prohibiting us from precision quantification of band molecular weight. 
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                1        2       3        4       5       6       7       8       9       10      11 
Figure 2.1. Proteolysis of 200 µM CCLP3, CCLP2 and CCLP3 bis-Cys by 2 µM 
Collagenase in Tris Buffer pH 7.4. Lane 1 contains MW standard. Lanes 2, 3, and 4 contain CCLP3 
stock, CCLP3 0 hr, and CCLP3 72 hr, respectively. Lanes 5, 6, and 7, contain CCLP2, CCLP2 0 hr, and 
CCLP2 72 hr respectively. Lanes 8, 9, and 10 contain CCLP3 bis-Cys, CCLP3 bis-Cys 0 hr, and CCLP3 
bis-Cys 72 hr. Lane 11 contains collagenase. 
 
 After observing cleavage, Collagenase concentration was decreased in order to 
more accurately observe cleavage of engineered proteins by physiologically relevant 
concentrations. The objective was now to determine the lifetime of CCLP2 and CCLP3 
when subjected to cleavage in extracellular matrix conditions that may occur during 
inflammation. Each gel corresponds to a specific construct at a pH of 5.7, 6.5, or 7.4 at 
37o C. We ran a standard protein ladder in the first lane of each gel so that we could 
accurately identify the main construct bands, as well as fragment bands, that are produced 
from the cleavage by collagenase. As seen in Graphs 2.1 and 2.2, we created a trend line 
from the standard protein ladder by plotting the logarithm base 10 of the molecular 
weight of each protein band vs. the relative mobility of each respective protein band. 
Using the equation of the trend line, we were able to accurately identify the molecular 
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weights of the band fragments that are formed, in order to determine if the large, 
Calmodulin-containing products were produced. 
 Figures 2.2, 2.3 and 2.4 show the results of the pH dependence of the proteolysis 
of CCLP3 by Collagenase. At pH 5.7, there was very little proteolysis of CCLP3 
indicating that the protease has low activity at this pH. At pH 6.5 (Figure 2.3) significant 
proteolysis is observed, including two intermediates that were relatively long-lived, and 
then the final, lower MW fragment that contains “trimmed” Calmodulin. Graph 2.1 was 
used to estimate the size of the fragments formed. The Calmodulin fragment had a 
calculated MW of 16,900 D, a value similar to the expected value. Although not identical 
to the Calmodulin peptide engineered into CCLP, it is likely Calmodulin with excess C-
terminal, and N-Terminal CLS residues that remained following collagenase cleavage. 
The intermediates appear at MW 36,000 D and 20,300 D. Immediate cleavage occurs 
forming an intermediate, when either N, or C terminal Calmodulin is cleaved off, 
resulting in an intermediate CCLP3 construct that has only two Calmodulins in the 
construct, as opposed to the original CCLP3 with three Calmodulins, and corresponds to 
the transient protein band at ~ 36,000 in Figure 2.3. This pattern implies an initial 
cleavage event, likely loss of the C-terminal fragment, and then subsequent internal 
cleavage to create two fragments that are then trimmed to the final Calmodulin unit at ~ 
17,000 D. The exact same intermediates are formed in the digest at pH 7.4 (Figure 2.4), 
but they persist longer. Taken together, this pH dependent study of proteolytic activity 
indicates that CCLP3 is a substrate for proteolysis and that the protease has highest 
activity at pH 6.5. 
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Figure 2.2. Proteolysis of CCLP3 by Collagenase in MES Buffer pH 5.7. Lane 1 contains 
the protein ladder, lane 2 contains collagenase, lane 3 contains CCLP3 stock, and lanes 4-11 contain 
CCLP3 digests times 0 min-640 min. 
 
 	1								2								3							4							5								6							7								8						9					10					11						12	
Figure 2.3. Proteolysis of CCLP3 by Collagenase in MES Buffer pH 6.5. Lane 1 contains 
the protein ladder, lane 2 contains collagenase, lane 3 contains CCLP3 stock, and lanes 4-12 contain 
CCLP3 digests times 0 min-1280 min. 
 
																																																					Stock			T0					T10				T20				T40				T80			T160			T320		T640	
																																								Stock				T0					T10				T20				T40				T80			T160			T320		T640		T1280	
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Figure 2.4. Proteolysis of CCLP3 by Collagenase in MES Buffer pH 7.4. Lane 1 contains 
the protein ladder, lane 2 contains collagenase, lane 3 contains CCLP3 stock, and lanes 4-12 contain 
CCLP3 digests times 0min-1280min. 
 
 
Graph 2.1: The trend-line formed from the Gel migration patterns of the protein ladder 
for examination of CCLP3 fragment identification in proteolysis. The logarithm base 10 
of the molecular weight plotted against the relative mobility of the MW standard protein 
ladder to produce a trend-line. The equation for the trend-line is then used to determine 
molecular weight identities for major bands. Major bands were determined to be 16,900 
kD, and 20,300 kD. 
 
  Figures 2.5 and 2.6 show the results of pH dependence of the proteolysis of 
CCLP2. This construct has only two Calmodulin sequences and each sequence is 
y	=	-1.4701x	+	5.0576	R²	=	0.96599	
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followed by 3 repeats of CLS. As such, proteolysis of this construct creates a feathered 
look to the low MW fragments, and no high MW fragment as observed in the CCLP3 
digest. This indicated that the cleavage at one of the CLS sites between the two 
Calmodulin sequences cleaves CCLP2 in half and then subsequently there is cleavage of 
the other CLS sites, creating the feathered, higher MW intermediates as the CLS sites are 
cleaved. Catalytic efficiency at pH 6.5 is difficult to observe due to cleavage of CCLP2 
main band forming band fragments that are indistinguishable. 
			 																					1								2							3							4						5						6						7							8						9					10					11						12							13 
Figure 2.5. Proteolysis of CCLP2 by Collagenase in MES Buffer pH 6.5. Lane 1 contains 
the protein ladder, lane 2 contains CCLP2 stock, lane 3 contains collagenase, and lanes 4-12 contain 
CCLP2 digests times 0 min-1280 min, and lane 13 contains 1280min digest with EDTA added. 
																												Stock								T0					T10				T20				T40				T80			T160			T320		T640		T1280		T*1280	
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Figure 2.6. Proteolysis of CCLP2 by Collagenase in Tris Buffer pH 7.4. Lane 1 contains the 
protein ladder, lane 2 contains CCLP2 stock, lane 3 contains collagenase  and lanes 4-12 contain CCLP2 
digests times 0 min-1280 min, and lane 13 contains 1280 min digest with EDTA added. 
 	
 
Graph 2.2. The trend-line formed from the Gel migration patterns of the protein ladder 
for examination of CCLP2 fragment identification. The logarithm base 10 of the 
molecular weight plotted against the relative mobility of the MW standard protein ladder 
to produce a trend-line. The equation for the trend-line is then used to determine 
molecular weight identities for major bands. Major band formed from digest was 
determined to be 21,000 kD.  
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 Once we observed pH- and time- dependent cleavage by collagenase, we decided 
to test pH- and time- dependence of Matrix-Metalloproteinases that are involved in the 
human inflammatory response. MMPs require activation, which entails cleaving a 
cysteine residue that interferes with the active site, before being catalytically active. Upon 
observation of Figure 2.7, and 2.8, notable similarities in molecular weights of Active, 
and inactive MMP-1, and MMP-8 imply either that the enzymes that we received were 
not MMP-1, and MMP-8, or that the activation protocol is incorrect. Lane 1 of each Gel 
is the standard protein ladder, and lanes 2-5 of Figure 2.7, and lanes 2-6 of Figure 2.8, are 
either active or inactive MMP-1, or active or inactive MMP-8 (exact identities are 
detailed in the figure legends). Despite the differences in identity of protease in each of 
these wells, the bands are strikingly similar in each of these wells, alluding to the fact that 
their actual identities are unknown.  
 
 																																											1										2										3													4												5													6												7													8												9					 
Figure 2.7. CCLP3 proteolysis by activated MMP-1. Apparent activation of MMP-1, and 
MMP-8 yielded no change in molecular weight when compared to the inactive, pro-
peptide form of the enzymes. Despite this, CCLP3 cleavage by MMP-1 was apparent but 
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minimal, which warrants further investigation into MMP activity. Lane 1 contains the protein 
ladder, lane 2 contains inactive MMP-1, lane 3 contains active MMP-1, lane 4 contains inactive MMP-8, 
lane 5 contains active MMP-8, lane 6, and 7 contain CCLP3 digest by MMP-1 0hr, and 16hr respectively, 
and lane 8, and 9 contain CCLP3 digest by MMP-8 0hr and 16hr respectively. 
 
 
 
 																							1									2									3							4								5								6												7							8					9									10							11						
 
Figure 2.8. CCLP3 proteolysis by activated MMP-1. Activation of MMP-1 and MMP-8 
yielded no change in molecular weight when compared to the inactive, pro-peptide forms 
of this enzyme, however cleavage of CCLP3 by MMP-1 is apparent, which warrants 
further investigation into MMP activity. Lane 1 contains the protein ladder, lane 2 contains the 
MMP-1inactive pro-enzyme, lane 3-6 contain activated MMP 0hr, 1hr, 2hr and 4hr respectively, lane 7 
contains CCLP3 sotck, Lane 8-11 contain CCLP3 digest by MMP-1 0hr, 16hr, 48hr, and 72hr 
respectively.* 
*Experimental errors in loading lanes 3,8,9, and 12 resulted in lower concentrations than other lanes, and 
can be disregarded. 
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CHAPTER 4  
CONCLUSION 
 Following extensive experimentation with collagenase at physiological 
temperature and differing physiological pHs, it can be concluded that the enzyme does 
exhibit pH dependence in activity. SDS-PAGE of CCLP3 digest by collagenase reveals 
that at 5.7 pH, the enzyme exhibited minimal activity, whereas proteolysis experiments 
carried out at 6.5 pH produced the optimal results, cleaving the specified site in the 
shortest amount of time, with proteolysis at pH 7.4 as a control. The proteolysis 
experiments of CCLP2 by collagenase at different pHs yielded results that are less clear. 
With CCLP2, it is difficult to make absolute statements regarding pH dependence due to 
main band CCLP2 fragments disappearing in both digests after approximately 80 
minutes, and secondary band formation being too close together to distinguish between 
bands. In order to optimize a gradual, pH dependent drug delivery, the CCLP3 construct 
is likely the best of our current construct for a hydrogel-based drug delivery system. 
 In order to accurately characterize fragments produced from the cleavage by 
collagenase, trend lines were formed from the known molecular weight ladder. The 
calmodulin peptide engineered into CCLP2 and CCLP3 has a molecular weight of 16,837 
D. The leader sequence of CCLP3 to the first cleavage site yields a band of 20,233 D. 
With the trend line, and known molecular weights of expected cleaved constructs, 
accurate identities of bands were determined. Formation of two distinct bands during 
CCLP3 digests corresponded to approximately 16,900 D and 20,300 D. The 16,900 D 
band can be distinguished as Calmodulin, and the band corresponding to 20,300 D is 
Calmodulin with the leader sequence engineered into the protein for His-Tag purification. 
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Due to many different cleavage points present in CCLP2, there are several different 
bands that can form with similar Molecular weights. Also, since single band resolution of 
the digested construct is poor, it is not possible to conclude which exact construct that 
includes calmodulin was formed. During CCLP2 SDS-PAGE characterization, final 1280 
minute samples were treated with EDTA, in order to chelate the Ca2+ from the 
Calmodulin in case the change in conformation upon calcium binding altered the 
migration of bands. Upon observation, it can be concluded that Ca2+ did not alter 
fragment migration by any observable amount.  
 We began investigation into specific Matrix Metalloproteinase pH dependent 
catalysis of engineered protein substrate, however due to gel anomalies, the project was 
put on hold. Activation of MMP-1 occurs through cleavage of the 52-57 kD pro-peptide 
form, altering the molecular weight by approximately 10 kD for MMP-1, resulting in a 
42-47kD active form depending on glycosylation. Activation of MMP-8 occurs through 
cleavage of the 85kD inactive form to produce an active 65-70kD activated form. Despite 
a discernable difference in molecular weights between the active and inactive forms of 
each respective MMP, it is evident by Figure 2.7, and Figure 2.8, the SDS-PAGE of the 
CCLP3 proteolysis experiments, each band, whether inactive or active, and whether 
MMP-1 or MMP-8, is strikingly similar in molecular mass. This warrants further research 
into the activation of MMP-1 and MMP-8, as well as the activity at physiological 
conditions in vitro.  
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APPENDIX  
 
The amino acid sequences of the proteins studied in this thesis. 
 
CCLP3 Construct 
MGSSHHHHHHSSGLVPRGSHMARMADQLTEEQIAEFKEAFSLFDKDGDGTITTK
ELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEE
EIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVN
YEEFVQMMTAKGSGYGGPQGI/WGQSGYGGSMADQLTEEQIAEFKEAFSLFDKD
GDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKM
KDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADID
GDGQVNYEEFVQMMTAKGSGYGGPQGI/WGQSGYGGSMADQLTEEQIAEFKEA
FSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLT
MMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDE
MIREADIDGDGQVNYEEFVQMMTAKGSGYGGPQGI/WGQGSGYGSRCR 
 
CCLP2 Construct 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSMADQLTEEQIAEFKEAFSL
FDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMM
ARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIR
EADIDGDGQVNYEEFVQMMTAKELQGPQG/IWGQGSGYGGPQG/IWGQGSGYG
GPQG/IWGQGRRSGYGGSMADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVM
RSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFR
VFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQ
MMTAK ELQGPQG/IWGQGSGYGGPQG/ IWGQGSGYGGPQG/IWGQGSGYGRSC   
 
CCLP3 bis-Cys 
MGSSHHHHHHSSGLVPRGSHMCRMADQLTEEQIAEFKEAFSLFDKDGDGTITTK
ELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEE
EIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVN
YEEFVQMMTAKGSGYGGPQG/IWGQSGYGGSMADQLTEEQIAEFKEAFSLFDKD
GDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKM
KDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADID
GDGQVNYEEFVQMMTAKGSGYGGPQG/IWGQSGYGGSMADQLTEEQIAEFKEA
FSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLT
MMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDE
MIREADIDGDGQVNYEEFVQMMTAKGSGYGGPQG/IWGQGSGYGSRCR 
 
PCLP 3  
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGS 
KRRWKKNFIAVSAANRFKKISSSGALELDSTQGPQG/IWGQGGRRSGYGGS 
KRRWKKNFIAVSAANRFKKISSSGALELDSTQGPQG/IWGQGSENSG 
KRRWKKNFIAVSAANRFKKISSSGALELDSTQGPQG/IWGQGSENSG 
RCR 
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A – CLS (collagen like sequence) 
A – Calmodulin  
A – Leader sequence for His-Tag Purification 
/ – Cleavage site  
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